2014 AG INNOVATION NATIONAL GENETICS SALE : Lot 90 TARANGOWER 12002 For more information, please visit: http://abri.une.edu.au/online/cgi-bin/i4.dll?1=3538202F 2=2934 3=56 5=2B3C2B3C3A 6=5F58255D265A21 9=5F5E5F5C 11=52505B5D 12=43425850. By: NZBullWalk … Continue reading →

Myriad Genetics ( MYGN ) reported earnings per share (EPS) of 60 cents in the third quarter of fiscal 2014, registering a remarkable 30.4% beat over the Zacks Consensus Estimate as well as the year-over-year adjusted number. EPS growth was boosted by a strong top line and a reduced share count. Without these adjustments, reported EPS came in at 48 cents, up 4.3% year over year. However, despite outperforming all estimates, shares of Myriad slashed 9.8% to close at $36.87 following the earnings release. Quarter in Detail Revenues increased 17% year over year to $182.9 million, sailing past the Zacks Consensus Estimate of $174 million. Growth was mainly driven by strong performance in the core markets, complemented by international expansion. According to the company, it is perfectly in sync with the strategic initiatives of expanding core hereditary cancer market, growing international business and launching new life-saving products. The company noted that, this quarter is more reflective of a true year-over-year performance sans the impact from additional publicity involving celebrities, which had otherwise acted as a major factorboosting revenues for the past few quarters. Segments in Detail Myriad operates through two major segments. Molecular diagnostic tests contributed 96% to total revenue … Continue reading →